Pascal Deschatelets - 16 Jan 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Chief Scientific Officer
Signature: /s/ David Watson, attorney-in-fact for Pascal Deschatelets
Issuer symbol: APLS
Transactions as of: 16 Jan 2024
Net transactions value: +$541,040
Form type: 4
Filing time: 17 Jan 2024, 16:47:27 UTC
Previous filing: 15 Nov 2023
Next filing: 23 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Award	$0	+6,743	+0.6%	$0.000000	1,123,550	16 Jan 2024	Direct	F1
transaction	APLS	Common Stock	Sale	$109,032	-1,632	-0.15%	$66.81	1,121,918	16 Jan 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Award	$650,072	+9,805		$66.30	9,805	16 Jan 2024	Common Stock	9,805	$66.30	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents an award of Restricted Stock Units granted 01/16/2024 that vests annually from grant date over a four year period subject to continued service.
F2	This represents shares sold to cover tax withholding on the Restricted Stock Units released on 01/12/2024.
F3	This represents a stock option award granted 01/16/2024 that vests over a four year period. 25% vests one year from grant date and the remaining 75% vests monthly thereafter subject to continued service.